Brief: Aravive Announces First Patient Dosed In Phase 3 Registrational Trial Evaluating Avb-500 In Patients With Platinum Resistant Ovarian Cancer
27/04/2021 13:28
April 27 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE ANNOUNCES FIRST PATIENT DOSED IN PHASE 3
REGISTRATIONAL
TRIAL EVALUATING AVB-500 IN PATIENTS WITH PLATINUM RESISTANT
OVARIAN CANCER
Source text for Eikon: ID:nGNX4W3g3W
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))